(Q48932547)

16 February 2018

title

Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. (English)

1 reference

16 February 2018

0 references

1 reference

M H Barnett

1

1 reference

16 February 2018

J W Prineas

2

1 reference

16 February 2018

M E Buckland

3

1 reference

16 February 2018

J D E Parratt

4

1 reference

16 February 2018

J D Pollard

5

1 reference

16 February 2018

publication date

25 August 2011

1 reference

16 February 2018

Multiple Sclerosis Journal

published in

1 reference

16 February 2018

volume

18

1 reference

16 February 2018

issue

1

1 reference

16 February 2018

page(s)

108-112

1 reference

16 February 2018

A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458511421185

Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511421185

Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511421185

Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511421185

A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511421185

Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511421185

Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511421185

Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511421185

Immunoglobulins and complement in postmortem multiple sclerosis tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511421185

Effects of natalizumab treatment on Foxp3+ T regulatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511421185

21 January 2018

Identifiers

DOI

10.1177/1352458511421185

1 reference

16 February 2018

PubMed ID

21868485

1 reference

16 February 2018